Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00859118
First received: March 9, 2009
Last updated: September 23, 2014
Last verified: September 2014

March 9, 2009
September 23, 2014
February 2009
May 2013   (final data collection date for primary outcome measure)
  • Determine pharmacodynamic change using FLT-PET/CT scans at baseline, during axitinib exposure and washout [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To evaluate objective response of axitinib in patients with advanced solid malignancies. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Determine pharmacodynamic change using FLT-PET/CT scans at baseline, during axitinib exposure and washout AND To evaluate objective response of axitinib in patients with advanced solid malignancies. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00859118 on ClinicalTrials.gov Archive Site
  • To measure change in plasma VEGF levels, during axitinib exposure and withdrawal [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Correlate axitinib pharmacokinetics with response, unexpected toxicity, VEGF levels, and FLT-PET/CT change. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Correlate vasculature kinetics extracted from the dynamic FLT PET/CT imaging with the vasculature kinetics extracted from DCE-CT [ Time Frame: 1 year ] [ Designated as safety issue: No ]
To measure change in plasma VEGF levels, during axitinib exposure and withdrawal AND correlate axitinib pharmacokinetics with response, unexpected toxicity, VEGF levels, and FLT-PET/CT change. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies

The main purpose of this study is to see what changes happen to the tumors while taking the axitinib and after it is stopped (during the scheduled breaks), and what changes in the tumor may be responsible for this growth. This will be done by using a special kind of scan called an 18F-FLT PET/CT.

In addition, the investigators want to find out how the drugs are processed and distributed in the human body. The investigators will also look at how different types of cancer are affected by axitinib. The investigators will also correlate vasculature kinetics extracted from the dynamic FLT PET/CT imaging with the vasculature kinetics extracted from DCE-CT.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Malignancies
  • Drug: AG-013736
    Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
    Other Name: Axitinib
  • Drug: AG-013736
    Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
    Other Name: Axitinib
  • Experimental: Schedule A Cohort 1

    Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.

    Scan#1: Baseline (days -3 to 0) Scan#2: Week 2 (between days 12-14) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans.

    Intervention: Drug: AG-013736
  • Experimental: Schedule A: Cohort 2

    Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.

    Scan#1: Week 2 (between days 12-14) Scan#2: Week 3 (2 days after axitinib held) Scan#3: Week 3 (7 days after axitinib held) Up to 10 patients will receive 2 DCE-CT scans at week 2 and 3, coinciding with the FLT-PET scans.

    Intervention: Drug: AG-013736
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
December 2014
May 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have histologically or cytologically confirmed solid malignancy (excluding lymphoma) that is metastatic or unresectable and for which no standard therapy exists (although all solid malignancies will be enrolled, a subset will be designated for NSCL cancer will be given due to planned trials in this disease.

    • must have measurable disease
    • Must be greater than or equal to 18 years old.
    • Life expectancy of greater than 12 weeks.
    • ECOG performance status less than or equal to 2.
    • Patients must have normal organ and marrow function
    • Must be willing to undergo planned pharmacodynamic assessments, including serial PET imaging, plasma markers, and pharmacokinetic sampling.
    • Women of childbearing potential and men must use adequate form of birth (hormonal or barrier method of birth control
    • must have ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

  • Must not havehad chemotherapy, radiotherapy, experimental therapy or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (to grade less than or equal to 1 or baseline) from clinically significant adverse events due to agents administered more than 4 weeks earlier (alopecia and fatigue excluded).

    • Patients may not be receiving any other investigational agents.
    • Prior anti-VEGF directed therapy may be allowed only if approved by the PI
    • Must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to axitinib.
    • Must not have poorly controlled hypertension (systolic blood pressure of 140 mmHg or higher or diastolic blood pressure of 90 mmHg or higher)
  • Must not require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis.

    • Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain axitinib tablets are excluded.
    • Patients with any of the following conditions are excluded:

      • Serious or non-healing wound, ulcer, or bone fracture.
      • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment.
      • Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry.
      • History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to study entry.
      • History of pulmonary embolism within the past 12 months.
      • Class III or IV heart failure as defined by the NYHA functional classification system.
    • Patients without appropriate lesion on CT scan for FLT-PET/CT imaging will be excluded.
    • The eligibility of patients taking medications that are potent inducers or inhibitors of that enzyme will be determined following a review of their case by the Principal Investigator.
    • Steroid use is not recommended during axitinib treatment unless absolutely necessary
    • Patients with a pre-existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible. Patients with a history of hypothyroidism are eligible provided they are currently euthyroid.
    • Must not have known brain metastases are excluded.
    • Must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infections or psychiatric illness/social situations that would limit compliance with study requirements
    • Must not be pregnant or breastfeeding.
    • Must not be HIV-positive on combination antiretroviral therapy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00859118
08905
Yes
University of Wisconsin, Madison
University of Wisconsin, Madison
Pfizer
Principal Investigator: Glenn Liu, M.D. University of Wisconsin, Madison
University of Wisconsin, Madison
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP